Skip to main content

Table 1 Clinicopathological characteristics of eligible studies

From: Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test

Study [Ref.] Country miRNA-130a miRNA-130b Histology TNM stage Sample Assay Follow-up (months) Cut-off HR (95% CI)
OS Other OS Other OS DFS/PFS
Jia 2019 [44] China 284     Gastric cancer I–IV Frozen tissue qRT-PCR 50 Median 2.44 (1.35,4.40)  
Peng 2018 [18] China 333 DFS,333    Gastric cancer I–III Serum qRT-PCR 59 Median 1.49 (0.99,2.26) 1.38 (0.99,1.91)
Liu 2018 [45] China 369     Colorectal cancer I–IV Serum qRT-PCR 60 Median 2.36 (1.07,5.22)  
Yang 2018 [46] China 60 DFS,60    Colorectal cancer I–IV Frozen tissue qRT-PCR 70 Median 2.25 (1.05,4.83)  
Asukai 2017 [16] Japan 27 DFS,27    Cholangiocarcinoma NA Frozen tissue qRT-PCR 82 Median 2.36 (1.18,4.17) 2.47 (1.10,5.56)
Zhou 2017 [47] China 51     HCC I–III Frozen tissue qRT-PCR 42 Normal 1.23 (0.78,1.96)  
Chen 2016 [11] China 86 DFS,86    Osteosarcoma I–IV Frozen tissue qRT-PCR 60 Median 2.14 (1.14,4.02) 2.04 (1.22,3.40)
Jiang 2016 [17] China 41     Gastric cancer I–III Frozen tissue qRT-PCR 36 Normal 2.05 (1.03,4.08)  
Yuan 2016 [14] China 56     Lymphoma NA Frozen tissue qRT-PCR 50 Median 1.23 (0.94,1.61)  
He 2014 [15] China 73 DFS,73    Cervical cancer I–IV Frozen tissue qRT-PCR 86 Normal 1.41 (0.30,6.63) 1.73 (0.14,21.52)
Li 2014 [21] China 102     HCC I–III Frozen tissue qRT-PCR 72 Normal 0.45 (0.22,0.90)  
Wang 2012 [48] China   DFS,100    NSCLC I–III Frozen tissue qRT-PCR 96 Normal   0.21 (0.09,0.50)
Hashimoto 2019 [49] America (AA)    36   Prostate cancer I–IV Frozen tissue qRT-PCR 260 Mean 22.4 (2.27,221.3)  
America (EA)    57   Prostate cancer I–IV Frozen tissue qRT-PCR 250 Mean 1.10 (0.21,5.74)  
Ulivi 2019 [50] Italy    83 DFS,85 NSCLC I–IIIA Serum qRT-PCR 160 Median 1.35 (1.08,1.69) 1.35 (1.08,1.69)
Hu 2018 [51] China    110   HCC NA Serum qRT-PCR 60 Median 6.58 (3.04,14.24)  
Ecke 2017 [52] Germany (TC)    100   Bladder-cancer NA Frozen tissue qRT-PCR 156 Median 0.99 (0.82,1.20)  
Germany (VC)    56   Bladder-cancer NA Frozen tissue qRT-PCR 156 Median 1.02 (0.53,1.96)  
Li 2017 [22] China    85   Glioma NA Frozen tissue qRT-PCR 36 Mean 2.22(1.38,3.56)  
Chang 2016 [23] China (TC)    85 DFS,85 HCC I–III Frozen tissue qRT-PCR 66 Normal 1.01 (0.38,2.72) 2.02 (1.33,3.07)
China (VC)    65 DFS,65 HCC I–III Frozen tissue qRT-PCR 80 Normal 1.93 (1.30,2.87) 1.73 (1.16,2.58)
Sheng 2015 [24] China    86   Glioma NA Frozen tissue qRT-PCR 36 Median 4.39 (1.50,12.82)  
Wang 2014 [25] China    97 DFS,97 HCC I–IV Frozen tissue qRT-PCR 60 Median 2.52 (1.24,5.15) 4.00 (1.52,10.54)
Kjersem 2014 [30] Norway    150 PFS,150 Colorectal cancer NA Serum qRT-PCR NA Median 1.31 (0.96,1.79) 1.40 (1.05,1.86)
Colangelo 2013 [26] Italy    80   Colorectal Cancer I–IV Frozen tissue qRT-PCR 108 Mean 5.99 (1.99,18.03)  
Zhao 2013 [31] China    52   Pancreatic cancer I–IV Frozen tissue qRT-PCR 36 Median 2.84 (1.25,6.45)  
Nakatani 2012 [53] Italy    49   Sarcoma NA Frozen tissue qRT-PCR 217 Median 2.11 (1.22,3.63)  
  1. NSCLC, non-small cell lung cancer; HCC, hepatocellular cancer; qRT-PCR, quantitative real-time PCR; OS, overall survival; PFS, progressive free survival; DFS, disease free survival; SC, survival curve; AA, African-American; EA, European-American; TC,Training cohort; VC, Validation cohort